Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Binafuxi granules for common cold with heat syndrome
ChiCTR2100053995Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of binafuxi in nasopharyngitis (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Disappearance rate of all symptoms after 3 days of treatment. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
binafuxi
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on ChiCTR2100053995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053995.